Synaptic proteins and choline acetyltransferase loss in visual cortex in dementia with Lewy Bodies

Journal of Neuropathology and Experimental Neurology

Volumn 72, Issue 1, 2013, Pages 53-60

  Mukaetova Ladinska, Elizabeta B ^a   Andras, Alina ^a   Milne, Joan ^a   Abdel All, Zeinab ^a   Borr, Iwo ^a   Jaros, Evelyn ^a,b   Perry, Robert H ^a,b   Honer, William G ^c   Cleghorn, Andrea ^d   Doherty, Jeanette ^d   Mcintosh, Gary ^d   Perry, Elaine K ^a   Kalaria, Raj N ^a   Mckeith, Ian G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Novocastra Laboratories Ltd   (United Kingdom)

Author keywords

Synuclein; ChAT activity; Dementia with Lewy body; Occipital lobe; SNAP 25; Synaptic proteins; Synaptophysin

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINE ACETYLTRANSFERASE; GAMMA SYNUCLEIN; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFUSE LEWY BODY DISEASE; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; OCCIPITAL CORTEX; PARIETAL CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; TEMPORAL CORTEX; VISUAL CORTEX;

AGED; AGED, 80 AND OVER; CHOLINE O-ACETYLTRANSFERASE; FEMALE; GAMMA-SYNUCLEIN; HUMANS; LEWY BODY DISEASE; MALE; NERVE TISSUE PROTEINS; PROSPECTIVE STUDIES; QA-SNARE PROTEINS; SYNAPTOPHYSIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; VISUAL CORTEX;

EID: 84871966429     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31827c5710     Document Type: Article

References (61)

1. Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies, but not in AD. Neurology 2001; 56:643-49
2. Fong TG, Inouye SK, Dai W, et al. Association cortex hypoperfusion in mild dementia with Lewy bodies: A potential indicator of cholinergic dysfunction? Brain Imaging Behav 2011;5:25-35
3. Shimizu S, Nayu H, Hirao K, et al. Value of analyzing deep gray matter and occipital lobe perfusion to differentiate dementia with Lewy bodies from Alzheimer's disease. Ann Nucl Med 2008;22:911-16
4. O'Brien JT. Role of imaging techniques in the diagnosis of dementia. Br J Radiology 2007;80:S71-77
5. Boecker H, Ceballos-Baumann AO, Volk D, et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007;64:984-88
6. Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012;33:2091-105
7. Fujishiro H, Iseki E,KasanukiK, et al. Glucose hypometabolism in primary visual cortex is commonly associated with clinical features of dementia with Lewy bodies regardless of cognitive conditions. Int J Geriatr Psychiatry 2012;27:1138-46
8. Albin RL, Minoshima S, D'Amato CJ, et al. Fluorodeoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462-66
9. Imamura T, Ishii K, Hirano N, et al. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). Neuroreport 1999;10:1903-7
10. Hamilton JM, Landy KM, Salmon DP, et al. Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies. Am J Geriatr Psychiatry 2012;20:773-81
11. Nagahama Y, Okina T, Suzuki N, et al. Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain 2010;133:557-67
12. Perry RH, Irving D, Blessed G, et al. Senile dementia of Lewy body type. J Neurol Sci 1990;95:119-39
13. Yamamoto R, Iseki E,Murayama N, et al. Investigation of Lewy pathology in the visual pathway of brains of dementia with Lewy bodies. J Neurol Sci 2006;246:95-101
14. Harrington CR, Perry RH, Perry EK, et al. Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia 1994;5:215-28
15. Perry EK, Haroutinian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. NeuroReport 1997;8:228-31
16. Reid RT, Sabbagh MMN, Corey-Bloom J, et al. Nicotinic receptor losses in dementia with Lewy bodies: Comparisons with Alzheimer's disease. Neurobiol Aging 2000;21:741-46
17. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international work shop. Neurology 1996;47:1113-24
18. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies. Third Report of the DLB Consortium. Neurology 2005;65:1863-72
19. Dewey ME, Copeland JRM, Lobo A, et al. Computerized diagnosis from a standardised history schedule: A preliminary communication about the organic section of the HAS-AGECAT system. Int J Ger Psychiatry 1992; 7:443-46
20. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149: 698-709
21. Ballard C, McKeith IG, Harrison R, et al. A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer's disease. Int Psychogeriatr 1997;9:381-88
22. Devanand DP, Miller L, Richards M, et al. The Columbia University scale of psychopathology in Alzheimer's disease. Arch Neurol 1992;49:371-76
23. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. II. Disorders of perception. Br J Psychiatry 1990;157:92-94
24. Gallagher DA, Parkkinen L, O'Sullivan SS, et al. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain 2011;134: 3299-3309
25. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
26. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 4:479-86
27. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;S1-2
28. Mukaetova-Ladinska EB, Garcia-Sierra F, Hurt J, et al. Staging of cytoskeletal and beta-Amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 2000;157:623-36
29. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75
30. Honer WG, Falkai P, Young C, et al. Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia. Neuroscience 1997;78:99-110
31. Mukaetova-Ladinska EB, Milne J, Andras A, et al. Alpha- And gammasynuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes. Dement Geriatr Cogn Disord 2008;26:32-42
32. Minger SL, Honer WG, Esiri MM, et al. Synaptic pathology in prefrontal cortex is present only with severe dementia in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:929-36
33. Mukaetova-Ladinska EB, Hurt J, Honer WG, et al. Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. Neurosci Lett 2002;317:161-65
34. Fonnum FA. A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 1975;24:407-9
35. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993;7: 69-79
36. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. NeuroReport 1994;5:747-49
37. Perry EK, Smith CJ, Court JA, et al. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J Neural Trans 1990;2:149-58
38. Bate C, Gentleman S, Williams A. >-SynucleinYinduced synapse damage is enhanced by amyloid-A1-42. Mol Neurodegener 2010;5:55
39. Wakabayashi K, Takahashi H, Obata K, et al. Immunocytochemical localization of synaptic vesicle-specific protein in Lewy bodyYcontaining neurons in Parkinson's disease. Neurosci Lett 1992;138:237-40
40. Wakabayashi K, Honer WG, Masliah E. Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Res 1994;19:24-32
41. Chen X, Xia Y, Alford M, et al. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Ann Neurol 1995;38: 653-658
42. Samuel W, Alford M, Hofstetter M, et al. Dementia with Lewy bodies versus pure Alzheimer disease: Differences in cognition, neuropathology, cholinergic dysfunction and synapse density. J Neuropathol Exp Neurol 1997;56:499-508
43. Hansen LA, Daniel SE, Wilcock GK, et al. Frontal cortical synaptophysin in Lewy body diseases: Relation to Alzheimer's disease and dementia. J Neurol Neurosurg Psychiatry 1998;64:653-56
44. Brown DF, Risser RC, Bigio EH, et al. Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: A comparison with classical Alzheimer disease and normal ageing. J Neuropathol Exp Neurol 1998;57:955-60
45. Campbell BC, Li Q-X, Culvenor JG, et al. Accumulation of insoluble >-synuclein in dementia with Lewy bodies. Neurobiol Dis 2000;7:192-200
46. Lippa CF. Synaptophysin immunoreactivity in Pick's disease: Comparison with Alzheimer's disease and dementia with Lewy bodies. Am J Alzheimer Dis Other Demen 2004;19:341-44
47. Revuelta GJ, Rosso A, Lippa CF. Neuritic pathology as a correlate of synaptic loss in dementia with Lewy bodies. Am J Alzheimers Dis Other Demen 2008;23:97-102
48. Dickson DW, Crystal HA, Bevona C, et al. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995;16:285-98
49. Hof PR, Morrison JH. The aging brain: Morphomolecular senescence of cortical circuits. Trends Neurosci 2004;27:607-13
50. Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience 2001;102:723-65
51. Watson R, Blamire AM, Colloby SJ, et al. Characterizing dementia with Lewy bodies by means of diffusion tensor imaging. Neurology 2012;79: 906-914
52. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 2007;68:2012-18
53. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27:1405-10
54. Garcia-Reitböck P, Anichtchik O, Bellucci A, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 2010;133:2032-44
55. Yoo MS, Chun HS, Son JJ, et al. Oxidative stress regulated genes in nigral dopaminergic neuronal cells: Correlation with the known pathology in Parkinson's disease. Brain Res Mol Brain Res 2003;110:76-84
56. Jenner P, Dexter DT, Sian J, et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992;32(Suppl):S82-87
57. Mukaetova-Ladinska EB, Xuereb JH, Garcia-Sierra F, et al. Lewy body variant of Alzheimer's disease: Selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe. Sci World J 2009;9:1463-75
58. Rockenstein E, Hansen L, Mallory M, et al. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 2001;914:48-56
59. Zhang H, Kouadio A, Cartledge D, et al. Role of gamma-synuclein in microtubule regulation. Exp Cell Res 2011;317:1330-39
60. Salem SA, Allsop D, Mann DM, et al. An investigation into the lipidbinding properties of alpha-, beta- And gamma-synucleins in human brain and cerebrospinal fluid. Brain Res 2007;1170:103-11
61. Pinhasov A, Ilyin SE, Crooke J, et al. Different levels of gamma-synuclein mRNA in the cerebral cortex of dominant, neutral and submissive rats selected in the competition test. Genes Brain Behav 2005;4:60-64